Publications:

---

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Signal Transduction And Targeted Therapy

Yang, Yang Y; Li, Shuo S; Wang, Yujiao Y; Zhao, Yi Y; Li, Qiu Q

Publication Date: 2022-09-17

Variant appearance in text: RET: L730I

PubMed Link: 36115852

Variant Present in the following documents:

• Main text
• 41392_2022_Article_1168.pdf

View BVdb publication page

---

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Frontiers In Endocrinology

Matrone, Antonio A; Gambale, Carla C; Prete, Alessandro A; Elisei, Rossella R

Publication Date: 2022

Variant appearance in text: RET: L730I

PubMed Link: 35422765

Variant Present in the following documents:

• Main text
• fendo-13-864253.pdf

View BVdb publication page

---

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.

Scientific Reports

Moccia, Marialuisa M; Yang, Donglin D; Lakkaniga, Naga Rajiv NR; Frett, Brendan B; McConnell, Nicholas N; Zhang, Lingtian L; Brescia, Annalisa A; Federico, Giorgia G; Zhang, Lingzhi L; Salerno, Paolo P; Santoro, Massimo M; Li, Hong-Yu HY; Carlomagno, Francesca F

Publication Date: 2021-08-09

Variant appearance in text: RET: L730I

PubMed Link: 34373541

Variant Present in the following documents:

• Main text
• 41598_2021_Article_95612.pdf

View BVdb publication page

---

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.

Npj Precision Oncology

Shen, Tao T; Hu, Xueqing X; Liu, Xuan X; Subbiah, Vivek V; Mooers, Blaine H M BHM; Wu, Jie J

Publication Date: 2021-06-07

Variant appearance in text: RET: L730I

PubMed Link: 34099825

Variant Present in the following documents:

• Main text
• 41698_2021_Article_188.pdf
• 41698_2021_188_MOESM1_ESM.pdf

View BVdb publication page

---

Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases.

Scientific Reports

Šimčíková, Daniela D; Heneberg, Petr P

Publication Date: 2019-12-09

Variant appearance in text: RET: L730I

PubMed Link: 31819097

Variant Present in the following documents:

• 41598_2019_54976_MOESM2_ESM.xlsx, sheet 8

View BVdb publication page

---

Drug resistance profiles of mutations in the RET kinase domain.

British Journal Of Pharmacology

Liu, Xuan X; Shen, Tao T; Mooers, Blaine H M BHM; Hilberg, Frank F; Wu, Jie J

Publication Date: 2018-09

Variant appearance in text: RET: L730I

PubMed Link: 29908090

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Investigational New Drugs

Kato, Shumei S; Jardim, Denis L DL; Johnson, Faye M FM; Subbiah, Vivek V; Piha-Paul, Sarina S; Tsimberidou, Apostolia M AM; Falchook, Gerald S GS; Karp, Daniel D; Zinner, Ralph R; Wheler, Jennifer J; Janku, Filip F; Fu, Siqing S; Lim, JoAnn J; Bean, Stacie S; Nguyen, Ly L; Urban, Susan S; Browne, Elsa E; Meric-Bernstam, Funda F; Hong, David S DS

Publication Date: 2018-06

Variant appearance in text: RET: L730I

PubMed Link: 29047029

Variant Present in the following documents:

• Main text

View BVdb publication page

---